LEO Pharma Acquires Dersimelagon for Rare Skin Diseases
BALLERUP, DENMARK, August 18, 2026 LEO Pharma has entered into an agreement to acquire worldwide rights to dersimelagon from...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
BALLERUP, DENMARK, August 18, 2026 LEO Pharma has entered into an agreement to acquire worldwide rights to dersimelagon from...
LONDON, August 18, 2026 Smith+Nephew and Imperial College London have launched a new five-year partnership to accelerate innovation in...
BEIJING, August 18, 2026 InnoCare Pharma announced that China’s Center for Drug Evaluation (CDE) of the National Medical Products...
BEIJING, Aug. 4, 2026 InnoCare Pharma announced that the China National Medical Products Administration (NMPA) Center for Drug Evaluation...
